Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10077.026 | 1.1639 | 1.9229 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10077.026 | 0.8823 | 0.4622 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | CGC-11047 | Polyamine analogue | 5000 | uM | 10077.026 | 0.3720 | -0.8312 | 0.3999 | ||
| MDA-MB-134-VI | HR+ | Luminal | CGC-11047 | Polyamine analogue | 200 | uM | 10077.026 | 1.1349 | 1.7444 | 0.3999 | ||
| MDA-MB-134-VI | HR+ | Luminal | CGC-11047 | Polyamine analogue | 1000 | uM | 10077.026 | 0.9483 | 0.7515 | 0.3999 | ||
| MDA-MB-134-VI | HR+ | Luminal | CGC-11047 | Polyamine analogue | 0.0128 | uM | 10077.026 | 1.3074 | 2.9095 | 0.3999 | ||
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10077.026 | 1.1474 | 1.8209 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | CGC-11047 | Polyamine analogue | 40 | uM | 10077.026 | 1.0613 | 1.3206 | 0.3999 | ||
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10077.026 | 1.1712 | 1.9695 | 0.3999 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.00064 | uM | 9258.03 | 1.0306 | 1.1557 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.0032 | uM | 9258.03 | 1.1336 | 1.7329 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.016 | uM | 9258.03 | 1.1486 | 1.8244 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.08 | uM | 9258.03 | 1.0758 | 1.3991 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 0.4 | uM | 9258.03 | 0.9722 | 0.8643 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 250 | uM | 9258.03 | 0.0024 | -1.0000 | 0.4015 | |
| HCC1395 | TNBC | Basal B | 5-FU | TYMS | TYMS | 1.23 | uM | 9258.03 | 1.1185 | 1.6433 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 10 | uM | 9258.03 | 0.3531 | -0.8503 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 2 | uM | 9258.03 | 0.7648 | 0.0256 | 0.4015 | |
| HCC1395 | TNBC | Basal B | 5-FU | TYMS | TYMS | 6.15 | uM | 9258.03 | 1.1030 | 1.5532 | 0.4015 | |
| HCC1395 | TNBC | Basal B | 5-FU | TYMS | TYMS | 30.7 | uM | 9258.03 | 1.0331 | 1.1689 | 0.4015 | |
| HCC1395 | TNBC | Basal B | 5-FU | TYMS | TYMS | 0.0492 | uM | 9258.03 | 1.2452 | 2.4532 | 0.4015 | |
| HCC1395 | TNBC | Basal B | 5-FU | TYMS | TYMS | 0.246 | uM | 9258.03 | 1.1669 | 1.9372 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 25.4 | uM | 9258.03 | 0.6663 | -0.2725 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 1.01 | uM | 9258.03 | 0.8020 | 0.1545 | 0.4015 | |
| HCC1395 | TNBC | Basal B | Gemcitabine | DNA replication | DNA replication | 5.07 | uM | 9258.03 | 0.6688 | -0.2655 | 0.4015 |